These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1925256)

  • 1. Role of immunotherapy in the treatment of bladder and renal cell carcinoma.
    Stone NN; Droller MJ
    Semin Surg Oncol; 1991; 7(4):239-43. PubMed ID: 1925256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
    Surolia I; Gulley J; Madan RA
    Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview of Emerging Immunotargets of Genitourinary Tumors.
    Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
    Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
    Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel immunotherapies in GU malignancies.
    Drakaki A; McDermott DF
    Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in genitourinary neoplasia.
    Droller MJ
    J Urol; 1985 Jan; 133(1):1-5. PubMed ID: 2578065
    [No Abstract]   [Full Text] [Related]  

  • 8. [The studies of natural killer cell activity in uro-genital cancer patients--investigation of natural killer cell activity from the standpoint of stage and antitumor therapy of genito-urinary tract carcinomas].
    Fukasawa K
    Nihon Hinyokika Gakkai Zasshi; 1988 Feb; 79(2):239-45. PubMed ID: 3226000
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolving immunotherapeutic strategies in bladder and renal cancer.
    Griffiths TR; Mellon JK
    Postgrad Med J; 2004 Jun; 80(944):320-7. PubMed ID: 15192163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Immunotherapies for Renal Cell Carcinoma.
    Al-Marrawi MY; Holder SL
    Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for renal cell cancer.
    Yang JC; Childs R
    J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses.
    Ogasawara M; Miyashita M; Ota S
    Ther Apher Dial; 2018 Jun; 22(3):266-277. PubMed ID: 29851270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based immunotherapy of renal cell carcinoma.
    Gitlitz BJ; Figlin RA; Pantuck AJ; Belldegrun AS
    Curr Urol Rep; 2001 Feb; 2(1):46-52. PubMed ID: 12084295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of immunotherapy for metastatic renal cell carcinoma.
    Fowler JE
    J Urol; 1986 Jan; 135(1):22-5. PubMed ID: 3510318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
    Bigot F; Bonnet C; Massard C
    Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of target antigens in specific immunotherapy for renal cell carcinoma.
    Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
    J Urol; 2007 Mar; 177(3):1157-62. PubMed ID: 17296437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
    Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
    J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
    Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.